Access to Anti-Obesity Medication for Medicare and Medicaid

By Rene Pretorius

December 9, 2024

The Biden administration’s proposal to expand anti-obesity medication coverage under Medicare and Medicaid focuses on improving access to these essential treatments for millions of Americans. With obesity affecting a large portion of the population, this initiative aims to tackle significant variations in access, cost, and coverage challenges.

Currently, millions of Americans struggle with obesity, yet access to effective anti-obesity medications is limited due to high costs and restrictive coverage policies. The proposed rule aims to expand access to these medications for approximately 3.4 million Medicare enrollees and 4 million Medicaid enrollees who are classified as obese, defined by a BMI of 30 kg/m² or higher. The out-of-pocket costs for anti-obesity medications can be prohibitively expensive, often exceeding $1,000 per month. This financial barrier prevents many individuals from accessing these life-saving treatments

Interventions to Overcome Low Anti-obesity Medication Coverage

Expanded Coverage:

The proposed rule would mandate that Medicare and Medicaid cover anti-obesity medications, significantly broadening access to these drugs. This expanded coverage includes medications like Wegovy (semaglutide), Ozempic (semaglutide), and Zepbound (tirzepatide).

Reduced Out-of-Pocket Costs:

The new proposal could reduce out-of-pocket costs for these prescription medications by as much as 95% for some Medicare enrollees. This change will make treatments more affordable and accessible.

Comprehensive Cost-Lowering Agenda:

The Biden administration is focused on a broader agenda to lower drug costs, which includes a drug price negotiation program and increased market competition. For example, the administration has successfully negotiated reduced prices for the first ten prescription drugs under Medicare, with savings ranging from 38% to 79% starting in 2026.

Addressing Health Disparities:

The expanded coverage will help reduce health disparities. It will particularly benefit low-income patients and Black and Hispanic individuals who often face barriers to accessing these essential medications.

Regulatory Changes:

The proposal would also tackle barriers to accessing care, such as inappropriate use of prior authorization. Notably, Medicare Advantage plans often reverse denials upon appeal, indicating that many enrollees might be missing out on necessary care due to initial rejections.

Financial Implications and Potential Opposition

The expanded coverage is projected to cost taxpayers up to $35 billion over the next decade. This raises concerns among proponents of reduced government spending. Potential opposition could arise from figures such as Robert F. Kennedy Jr., the nominated Head of the Department of Health and Human Services under the incoming administration.

In summary, the Biden administration’s proposal is a significant step towards enhancing access to anti-obesity medications by expanding coverage under Medicare and Medicaid, reducing out-of-pocket costs, and addressing broad cost and access challenges through comprehensive policy changes. By improving access to anti-obesity medications, we can help millions of individuals lead healthier lives.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.